高盛-石药集团(1093.HK):业绩回顾:2026年一季度成品药重回增长,原料药与许可收入入账拖累盈利-CSPC Pharma(1093.HK):Earnings Review:Finished drugs back to growth in 1Q;earnings dragged by API and booking of lice-20260528【7页】

发表回复

后才能评论